Dr. Reddy’s Cleared as U.S. DOJ Closes FCPA Inquiry Without Enforcement
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
On March 6, 2026, Dr. Reddy’s Laboratories announced that the U.S. Department of Justice has closed its inquiry into allegations of improper payments to healthcare professionals in Ukraine and potentially other countries. The probe, first disclosed in November 2020 and focused on potential violations of U.S. anti-corruption laws including the Foreign Corrupt Practices Act, had been investigated by an external U.S. law firm under the direction of the company’s board.
The company said the DOJ’s Fraud Section informed it on March 5, 2026, that the inquiry under the FCPA has been closed with no enforcement action recommended against Dr. Reddy’s. This follows a February 23, 2026 letter from the U.S. Securities and Exchange Commission similarly stating it did not intend to recommend enforcement, easing a multi-year regulatory overhang that had posed a risk of civil or criminal sanctions for the drugmaker and its stakeholders.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. It develops, manufactures and markets generic medicines and active pharmaceutical ingredients, with a strong presence in regulated markets including the U.S., as well as emerging markets such as parts of Eastern Europe.
Average Trading Volume: 1,662,333
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.96B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
